Drugs / intravenous immunmoglobulin
intravenous immunmoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03542279 | Nov 2020 → Dec 2022 | autoimmune encephalitis | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunmoglobulin | “intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)” NCT03542279 ↗ |
| Known as | intravenous immunoglobulin | “intravenous immunoglobulin (IVIG; 0.4 g/kg/d for each course for 5 d)” NCT03542279 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03542279 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIG; 0.4 g/kg/d for each course for 5 d)” NCT03542279 ↗ |
| Route | Intravenous | “intravenous immunoglobulin (IVIG; 0.4 g/kg/d for each course for 5 d)” NCT03542279 ↗ |